Share This

Topics Comments

Cheung Kong VODone Limited Shenzhen International Holdings Limited Jiangxi Copper Company Limited REXLot Holdings Limited China Overseas Land & Investment Limited Chong Hing Bank Limited Agricultural Bank of China Limited Chow Tai Fook Jewellery Group Limited Capital VC Limited iShares A50 Standard Chartered Bank of Communications Bank of China China LotSynergy Holdings Limited agribank Agri Airlines Appl AUD Auto A Shares Brokers CAD fertilizer producers China Lottery Supermarket China Banks Communication Consumer China Econ Electricity China Finance China IT Petro Real Est China Resource Steel coal Commodity Beauty Drugs Enviro EURO Lang Simon Ting WongSir Andy Xie Expo Gambling Garment gas GBD Gold Gold Jew Gold mine Harbour Highways HK Apparel REITs Rentals HK Banks ETF HK Housing Market Real Est HK HK Stock iBond Infra Insure IPO jewel Mach Build Mat New Energy NZD Oil Paper Rare Earths Real Estate Market Food RMB Rising RMB RMB Bonds Shipbuilding Shipping Sports Stock Trend Taiwan Dollar (TWD) Textile Top 500 USD US Econ Util Water Yang Liu's 10 Stocks YEN Diary media Central Bank Monetary Policy Education Construction Emerging markets Nuclear power BillGross Cement HK retail logistics Swiss franc Social Security Fund Law Ka-Chung capital flow Financial and political policy Railway film Korean Won Roubini Faber Mobius
Topics Last reply time Nickname Content
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 2022-08-22T11:24 財經茄呢啡 百奧賽圖(2315)業務可分為藥物開發及臨床前研究服務兩大範疇。在藥品開發業務方面,又可分為腫瘤學和自身免疫性疾病治療研發,及抗體開發業務。集團兩個核心產品:YH003主要針對胰腺導管腺癌、黑色素瘤及其他實體瘤的治療;YH001則主要針對非小細胞肺癌、肝細胞癌及其他實體瘤的治療。
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 2022-08-22T11:23 財經茄呢啡 生物製藥及臨床前研發服務公司百奧賽圖(2315)上周五開始招股,集資約5.49億元。集團利用獨有專利技術,提供生物醫藥研發及臨床試驗外包(CRO)雙線服務,業務較為獨特。

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.